Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus
Research
Conduit taps Charles River to build AZ asset’s autoimmune cred
AstraZeneca took the asset through phase 2 trials for diabetes, and Conduit announced licensing plans to pivot to autoimmune disease.
Darren Incorvaia
Feb 13, 2025 12:51pm
Biogen taps Royalty for $250M to fund phase 3 lupus program
Feb 12, 2025 8:10am
Cullinan CEO sets tone for bispecific's upcoming lupus readout
Feb 7, 2025 5:00am
BMS' CAR-T cracks down on lupus, achieving sustained responses
Nov 14, 2024 10:00am
Ventus to move daily oral lupus prospect into phase 2 testing
Oct 31, 2024 9:10am
GSK aims to extend lupus dominance via $300M T-cell engager deal
Oct 29, 2024 8:00am